CL2008002038A1 - Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder. - Google Patents

Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder.

Info

Publication number
CL2008002038A1
CL2008002038A1 CL2008002038A CL2008002038A CL2008002038A1 CL 2008002038 A1 CL2008002038 A1 CL 2008002038A1 CL 2008002038 A CL2008002038 A CL 2008002038A CL 2008002038 A CL2008002038 A CL 2008002038A CL 2008002038 A1 CL2008002038 A1 CL 2008002038A1
Authority
CL
Chile
Prior art keywords
oxazole
phenyl
treatment
compounds derived
sodium channel
Prior art date
Application number
CL2008002038A
Other languages
Spanish (es)
Inventor
Yevgeni Besidski
Alf Claesson
Istvan Macsari
Lars Sandberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008002038A1 publication Critical patent/CL2008002038A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de fenil 1,2 oxazol y su uso para el tratamiento de un trastorno del dolor.Compounds derived from phenyl 1,2 oxazole and their use for the treatment of a pain disorder.

CL2008002038A 2007-07-13 2008-07-11 Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder. CL2008002038A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94966507P 2007-07-13 2007-07-13

Publications (1)

Publication Number Publication Date
CL2008002038A1 true CL2008002038A1 (en) 2009-07-17

Family

ID=39709355

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002038A CL2008002038A1 (en) 2007-07-13 2008-07-11 Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder.

Country Status (6)

Country Link
AR (1) AR067513A1 (en)
CL (1) CL2008002038A1 (en)
PE (1) PE20090477A1 (en)
TW (1) TW200911766A (en)
UY (1) UY31219A1 (en)
WO (1) WO2009010784A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537180A (en) * 2010-09-13 2013-09-30 ノバルティス アーゲー Triazine-oxadiazoles
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MX2014014234A (en) 2012-05-22 2015-05-07 Genentech Inc N-substituted benzamides and their use in the treatment of pain.
KR101663436B1 (en) 2012-07-06 2016-10-06 제넨테크, 인크. N-substituted benzamides and methods of use thereof
KR20150131233A (en) 2013-03-14 2015-11-24 제넨테크, 인크. Substituted triazolopyridines and methods of use thereof
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CR20160296A (en) 2013-11-27 2016-09-20 Genentech Inc BENZAMIDS REPLACED AND METHODS TO USE THEM
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR20180008761A (en) 2015-05-22 2018-01-24 제넨테크, 인크. Substituted benzamides and methods for their use
JP2018526371A (en) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド Therapeutic compounds and methods of use thereof
RU2018115718A (en) 2015-09-28 2019-10-28 Дженентек, Инк. THERAPEUTIC COMPOUNDS AND WAYS OF THEIR APPLICATION
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
MX2019004232A (en) 2016-10-17 2019-08-01 Genentech Inc Therapeutic compounds and methods of use thereof.
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
JP2021519788A (en) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Condensation ring hydropyrido compound as a sodium channel inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors

Also Published As

Publication number Publication date
PE20090477A1 (en) 2009-05-24
TW200911766A (en) 2009-03-16
WO2009010784A1 (en) 2009-01-22
AR067513A1 (en) 2009-10-14
UY31219A1 (en) 2009-03-02

Similar Documents

Publication Publication Date Title
CL2008002038A1 (en) Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder.
CL2008002998A1 (en) Piperazine-1-carboxamide derived compounds, faah inhibitor; pharmaceutical composition comprising said compound; and use of the compound for the treatment of inflammatory or neuropathic pain, anxiety and depression.
GEP20237506B (en) Pcsk9 antagonist compounds
ECSP088286A (en) AMINO-5- [4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF THE ß-SECRETASE
CL2011001389A1 (en) Isoxazoline derivative compounds; composition comprising one of the compounds; and use of the compounds in parasite control.
CL2011001497A1 (en) Compounds derived from heterocycles, gpr120 modulator; pharmaceutical composition; and its use for the treatment of type I, ii diabetes and metabolic syndrome.
CL2007001670A1 (en) Use of amine-derived compounds for the treatment of a cytokine-mediated disorder.
CL2013000685A1 (en) Compounds derived from n- (phenyl / benzyl) -6- (1,2,4-oxadiazol-3-yl) -1,3,5-triazin-2,4-diamine; sodium channel blockers (nav 1.7); pharmaceutical composition; that understands them; use in the treatment of chronic pain.
CL2008000795A1 (en) USE OF 1- [2- (2,4-DIMETILFENILSULFANIL) PHENYL) PIPERAZINE FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
CL2007002974A1 (en) COMPOUNDS DERIVED FROM BENZOIMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DGAT1.
CL2011000835A1 (en) Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others.
GT200900260A (en) ANTICOAGULANT CONVINTION THERAPY WITH A COMPOUND THAT ACTS AS AN INHIBITOR OF THE XA FACTOR
CL2008001024A1 (en) Phthalazinone derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cardiovascular diseases, parkinson's, inflammatory diseases, multiple sclerosis, cancer, among others
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
DK1861100T3 (en) 3,11B-cis-dihydrotetrabenazine for the treatment of a profiler disease or inflammation
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
CO6321285A2 (en) USE OF 3,11B-CIS- DIHIDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND SELF-IMMUNE HONEY MIELITIS
BRPI0709769B8 (en) Biodegradable implants for the treatment of conditions associated with dopamine
CL2007002479A1 (en) COMPOUNDS DERIVED FROM PIRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS.
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
CL2008001728A1 (en) Compounds derived from indolinones; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer, infections, inflammatory and autoimmune diseases.
BRPI0821696A2 (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
CL2008000110A1 (en) USE OF COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED FOR THE TREATMENT OF METABOLIC SYNDROME; AND COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED.
CL2012000640A1 (en) Use of the compound n- (4 - ((3- (2-amino-4-pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine or its salt for the treatment of cancer refractory to treatment with an anti-cancer agent.
CL2009001012A1 (en) A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon.